A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, in subjects with advanced pancreatic cancer.

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 44; pp. 702 - 847
Autores principales: Berg, Julia, Bullock, Andrea J., Whooley, Peter D., Peters, Mary Linton Bounetheau, Horick, Nora K., Zerillo, Jessica Ann, Rattani, Ahmed Anwer Ali, Schlechter, Benjamin L., Sinanovic, Selma, Martin, Jane, Montgomery, Casey, Eaton, Elizabeth, Vyas, Monika, Muranen, Taru E., Hidalgo, Manuel, Bockorny, Bruno
Formato: Journal Article
Publicado: American Society of Clinical Oncology 2026 Supplsmsnr 2
Acceso en línea:Ver este registro en EBSCOhost